Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 322

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial

Bakker, Marije F., Jacobs, Johannes W.G., Welsing, Paco M.J., Verstappen, Suzanne M.M., Tekstra, Janneke, Ton, Evelien, Geurts, Monique A.W., van der Werf, Jacobine H., van Albada-Kuipers, Grietje A., Jahangier-de Veen, Zalima N., van der Veen, Maaike J., Verhoef, Catharina M., Lafeber, Floris P.J.G., Bijlsma, Johannes W.J., on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group* · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: Treatment strategies for tight control of early rheumatoid arthritis (RA) are highly effective but can be improved. OBJECTIVE: To investigate whether adding prednisone, 10 mg/d, at the start of a methotrexate (MTX)-based treatment strategy for tight control in early RA increases its effectiveness. DESIGN: A 2-year, prospective, randomized, placebo-controlled, double-blind, multicenter trial (CAMERA-II [Computer Assisted Management in Early Rheumatoid Arthritis trial-II]). (International Standard Randomised Controlled Trial Number: ISRCTN 70365169) SETTING: 7 hospitals in the Netherlands. PATIENTS: 236 patients with early RA (duration <1 year). INTERVENTION: Patients were randomly assigned to an MTX-based, tight control strategy starting with either MTX and prednisone or MTX and placebo. Methotrexate treatment was tailored to the individual patient at monthly visits on the basis of predefined response criteria aiming for remission. MEASUREMENTS: The primary outcome was radiographic erosive joint damage after 2 years. Secondary outcomes included response criteria, remission, and the need to add cyclosporine or a biologic agent to the treatment. RESULTS: Erosive joint damage after 2 years was limited and less in the group receiving MTX and prednisone (n = 117) than in the group receiving MTX and placebo (n = 119). The MTX and prednisone strategy was also more effective in reducing disease activity and physical disability, achieving sustained remission, and avoiding the addition of cyclosporine or biologic treatment. Adverse events were similar in both groups, but some occurred less in the MTX and prednisone group. LIMITATION: A tight control strategy for RA implies monthly visits to an outpatient clinic, which is not always feasible. CONCLUSION: Inclusion of low-dose prednisone in an MTX-based treatment strategy for tight control in early RA improves patient outcomes. PRIMARY FUNDING SOURCE: Catharijne Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-156-5-201203060-00004

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 322

Metadata

Authors
Bakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Jahangier-de Veen, Z. N., van der Veen, M. J., Verhoef, C. M., Lafeber, F. P. J. G., Bijlsma, J. W. J., & on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group*
Venue
Annals of Internal Medicine
Published
2012-03-06
Volume
156
Issue
5
Pages
329-339
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2155195115
Cited by
322
References
28
FWCI
30.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-156-5-201203060-00004
The paper
Bakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Jahangier-de Veen, Z. N., van der Veen, M. J., Verhoef, C. M., Lafeber, F. P. J. G., Bijlsma, J. W. J., & on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group*. (2012). Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-5-201203060-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.